Human genetics as a model for target validation: finding new therapies for diabetes

Diabetologia

Volumn 60, Issue 6, 2017, Pages 960-970

  Thomsen, Soren K ^a   Gloyn, Anna L ^a,b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

Adverse effects; Genome wide association studies; Human genetics; Monogenic diabetes; Precision medicine; Review; Target discovery; Target validation; Therapeutic mechanisms; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCOKINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; REGULATOR PROTEIN; SODIUM GLUCOSE COTRANSPORTER 2; SULFONYLUREA DERIVATIVE;

DRUG MECHANISM; GENETIC VARIABILITY; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN GENETICS; MENDELIAN RANDOMIZATION ANALYSIS; MONOGENIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; VALIDATION STUDY; ANIMAL; GENETICS;

ANIMALS; DIABETES MELLITUS, TYPE 2; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN GENETICS; HUMANS; PRECISION MEDICINE;

EID: 85018287097     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-017-4270-y     Document Type: Review

References (90)

1. IDF (2015) International diabetes federation diabetes atlas, 7th edn. International Diabetes Federation, Belgium. Available from http://www.diabetesatlas.org. Accessed 1 March 2017
2. DiMasi JA, Feldman L, Seckler A, Wilson A (2010) Trends in risks associated with new drug development: success rates for investigational drugs. Clin Pharmacol Ther 87:272–277
3. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33
4. Arrowsmith J, Miller P (2013) Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov 12:569
5. Cook D, Brown D, Alexander R et al (2014) Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13:419–431
6. Wehling M (2009) Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Discov 8:541–546
7. Plenge RM, Scolnick EM, Altshuler D (2013) Validating therapeutic targets through human genetics. Nat Rev Drug Discov 12:581–594
8. Barrett JC, Dunham I, Birney E (2015) Using human genetics to make new medicines. Nat Rev Genet 16:561–562
9. Hindorff LA, Sethupathy P, Junkins HA et al (2009) Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 106:9362–9367
10. MacArthur DG, Manolio TA, Dimmock DP et al (2014) Guidelines for investigating causality of sequence variants in human disease. Nature 508:469–476
11. Kryukov GV, Pennacchio LA, Sunyaev SR (2007) Most rare missense alleles are deleterious in humans: implications for complex disease and association studies. Am J Hum Genet 80:727–739
12. Goldstein DB, Allen A, Keebler J et al (2013) Sequencing studies in human genetics: design and interpretation. Nat Rev Genet 14:460–470
13. Fuchsberger C, Flannick J, Teslovich TM et al (2016) The genetic architecture of type 2 diabetes. Nature 536:41–47
14. Zuk O, Schaffner SF, Samocha K et al (2014) Searching for missing heritability: designing rare variant association studies. Proc Natl Acad Sci U S A 111:E455–E464
15. Flannick J, Beer NL, Bick AG et al (2013) Assessing the phenotypic effects in the general population of rare variants in genes for a dominant Mendelian form of diabetes. Nat Genet 45:1380–1385
16. Begg CB (2002) On the use of familial aggregation in population-based case probands for calculating penetrance. J Natl Cancer Inst 94:1221–1226
17. Zhou K, Pedersen HK, Dawed AY, Pearson ER (2016) Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nat Rev Endocrinol 12:337–346
18. Price AL, Spencer CC, Donnelly P (2015) Progress and promise in understanding the genetic basis of common diseases. Proc R Soc B 282:20151684
19. Nelson MR, Tipney H, Painter JL et al (2015) The support of human genetic evidence for approved drug indications. Nat Genet 47:856–860
20. Hauner H (2002) The mode of action of thiazolidinediones. Diabetes Metab Res Rev 18(Suppl 2):S10–S15
21. Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76–80
22. Deeb SS, Fajas L, Nemoto M et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284–287
23. Yen CJ, Beamer BA, Negri C et al (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270–274
24. Majithia AR, Flannick J, Shahinian P et al (2014) Rare variants in PPARG with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes. Proc Natl Acad Sci U S A 111:13127–13132
25. Mahajan A (2014) Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility. Nat Genet 46:234–244
26. Janbon M, Chaptal J, Vedel A, Schaap J (1942) Accidents hypoglycémiques graves par un sulfamidothiodiazol (le VK 57 ou 2254 RP). Montp Med 441:21–22
27. Gloyn AL, Weedon MN, Owen KR et al (2003) Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 52:568–572
28. Hani EH, Boutin P, Durand E et al (1998) Missense mutations in the pancreatic islet beta cell inwardly rectifying K+ channel gene (KIR6.2/BIR): a meta-analysis suggests a role in the polygenic basis of type II diabetes mellitus in Caucasians. Diabetologia 41:1511–1515
29. Gloyn AL, Hashim Y, Ashcroft SJ, Ashfield R, Wiltshire S, Turner RC (2001) Association studies of variants in promoter and coding regions of beta-cell ATP-sensitive K-channel genes SUR1 and Kir6.2 with type 2 diabetes mellitus (UKPDS 53). Diabet Med 18:206–212
30. Hamming KS, Soliman D, Matemisz LC et al (2009) Coexpression of the type 2 diabetes susceptibility gene variants KCNJ11 E23K and ABCC8 S1369A alter the ATP and sulfonylurea sensitivities of the ATP-sensitive K(+) channel. Diabetes 58:2419–2424
31. Proks P, Reimann F, Green N, Gribble F, Ashcroft F (2002) Sulfonylurea stimulation of insulin secretion. Diabetes 51(Suppl 3):S368–S376
32. Sladek R, Rocheleau G, Rung J et al (2007) A genome-wide association study identifies novel risk loci for type 2 diabetes. Nature 445:881–885
33. Rutter GA, Chimienti F (2015) SLC30A8 mutations in type 2 diabetes. Diabetologia 58:31–36
34. Flannick J, Thorleifsson G, Beer NL, Jacobs SB (2014) Loss-of-function mutations in SLC30A8 protect against type 2 diabetes. Nat Genet 46:357–363
35. Bush WS, Oetjens MT, Crawford DC (2016) Unravelling the human genome-phenome relationship using phenome-wide association studies. Nat Rev Genet 17:129–145
36. Shiota C, Coffey J, Grimsby J, Grippo JF, Magnuson MA (1999) Nuclear import of hepatic glucokinase depends upon glucokinase regulatory protein, whereas export is due to a nuclear export signal sequence in glucokinase. J Biol Chem 274:37125–37130
37. Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42:105–116
38. Lloyd DJ, St Jean DJ Jr, Kurzeja RJ et al (2013) Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 504:437–440
39. Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8:399–416
40. Saxena R, Voight BF, Lyssenko V et al (2007) Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 316:1331–1336
41. Orho-Melander M, Melander O, Guiducci C et al (2008) Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes 57:3112–3121
42. Johansen CT, Wang J, Lanktree MB et al (2010) Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. Nat Genet 42:684–687
43. Beer NL, Tribble ND, McCulloch LJ et al (2009) The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver. Hum Mol Genet 18:4081–4088
44. Rees MG, Wincovitch S, Schultz J et al (2012) Cellular characterisation of the GCKR P446L variant associated with type 2 diabetes risk. Diabetologia 55:114–122
45. Rees MG, Ng D, Ruppert S et al (2012) Correlation of rare coding variants in the gene encoding human glucokinase regulatory protein with phenotypic, cellular, and kinetic outcomes. J Clin Invest 122:205–217
46. Rees MG, Raimondo A, Wang J et al (2014) Inheritance of rare functional GCKR variants and their contribution to triglyceride levels in families. Hum Mol Genet 23:5570–5578
47. Meininger GE, Scott R, Alba M et al (2011) Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 34:2560–2566
48. De Ceuninck F, Kargar C, Ilic C et al (2013) Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 168:339–353
49. Chao EC (2014) SGLT-2 inhibitors: a new mechanism for glycemic control. Clin Diabetes 32:4–11
50. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J (2005) Phlorizin: a review. Diabetes Metab Res Rev 21:31–38
51. Kanai Y, Lee WS, You G, Brown D, Hediger MA (1994) The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 93:397–404
52. van den Heuvel LP, Assink K, Willemsen M, Monnens L (2002) Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet 111:544–547
53. Tancredi M, Rosengren A, Svensson AM et al (2015) Excess mortality among persons with type 2 diabetes. N Engl J Med 373:1720–1732
54. Marsh DJ, Dahia PL, Caron S et al (1998) Germline PTEN mutations in Cowden syndrome-like families. J Med Genet 35:881–885
55. Pal A, Barber TM, Van de Bunt M et al (2012) PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med 367:1002–1011
56. Smith GD, Ebrahim S (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1–22
57. Smith GD, Ebrahim S (2004) Mendelian randomization: prospects, potentials, and limitations. Int J Epidemiol 33:30–42
58. Schmidt AF, Swerdlow DI, Holmes MV et al (2016) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 5:97–105
59. Ference BA, Robinson JG, Brook RD et al (2016) Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 375:2144–2153
60. Rastegar-Mojarad M, Ye Z, Kolesar JM, Hebbring SJ, Lin SM (2015) Opportunities for drug repositioning from phenome-wide association studies. Nat Biotechnol 33:342–345
61. Sanseau P, Agarwal P, Barnes MR et al (2012) Use of genome-wide association studies for drug repositioning. Nat Biotechnol 30:317–320
62. Sanseau P, Agarwal P, Barnes MR et al (2013) Reply to rational drug repositioning by medical genetics. Nat Biotechnol 31:1082
63. Wang ZY, Zhang HY (2013) Rational drug repositioning by medical genetics. Nat Biotechnol 31:1080–1082
64. Althari S, Gloyn AL (2015) When is it MODY? Challenges in the interpretation of sequence variants in MODY genes. Rev Diabet Stud 12:330–348
65. Gloyn AL, Pearson ER, Antcliff JF et al (2004) Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 350:1838–1849
66. Pearson ER, Flechtner I, Njolstad PR et al (2006) Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations. N Engl J Med 355:467–477
67. Sagen JV, Raeder H, Hathout E et al (2004) Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 53:2713–2718
68. Shepherd M, Pearson ER, Houghton J, Salt G, Ellard S, Hattersley AT (2003) No deterioration in glycemic control in HNF-1alpha maturity-onset diabetes of the young following transfer from long-term insulin to sulphonylureas. Diabetes Care 26:3191–3192
69. Pearson ER, Pruhova S, Tack CJ et al (2005) Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4alpha mutations in a large European collection. Diabetologia 48:878–885
70. Pearson ER, Starkey BJ, Powell RJ, Gribble FM, Clark PM, Hattersley AT (2003) Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet 362:1275–1281
71. McCarthy MI (2017) Painting a new picture of personalised medicine for diabetes. Diabetologia 60:793–799
72. Gale EAM (2006) Declassifying diabetes. Diabetologia 49:1989–1995
73. Franks PW, McCarthy MI (2016) Exposing the exposures responsible for type 2 diabetes and obesity. Science 354:69–73
74. Thomsen SK, Gloyn AL (2014) The pancreatic beta cell: recent insights from human genetics. Trends Endocrinol Metab 25:425–434
75. Steinthorsdottir V, Thorleifsson G, Sulem P (2014) Identification of low-frequency and rare sequence variants associated with elevated or reduced risk of type 2 diabetes. Nat Genet 46:294–298
76. Bouatia-Naji N, Rocheleau G, Van Lommel L et al (2008) A polymorphism within the G6PC2 gene is associated with fasting plasma glucose levels. Science 320:1085–1088
77. Chen WM, Erdos MR, Jackson AU et al (2008) Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J Clin Invest 118:2620–2628
78. Mahajan A, Sim X, Ng HJ et al (2015) Identification and functional characterization of G6PC2 coding variants influencing glycemic traits define an effector transcript at the G6PC2-ABCB11 locus. PLoS Genet 11:e1004876
79. Wessel J, Chu AY, Willems SM et al (2015) Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility. Nat Commun 6:5897
80. Thomsen SK, McCarthy MI, Gloyn AL (2016) The importance of context: uncovering species- and tissue-specific effects of genetic risk variants for type 2 diabetes. Front Endocrinol 7:112
81. Moltke I, Grarup N, Jorgensen ME et al (2014) A common Greenlandic TBC1D4 variant confers muscle insulin resistance and type 2 diabetes. Nature 512:190–193
82. GTEx Consortium (2015) Human genomics. The genotype-tissue expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348:648–660
83. Voight BF, Scott LJ, Steinthorsdottir V et al (2010) Twelve type 2 diabetes susceptibility loci identified through large-scale association analysis. Nat Genet 42:579–589
84. Dimas AS, Lagou V, Barker A et al (2014) Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63:2158–2171
85. Fadista J, Vikman P, Laakso EO et al (2014) Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. Proc Natl Acad Sci U S A 111:13924–13929
86. van de Bunt M, Manning Fox JE, Dai X et al (2015) Transcript expression data from human islets links regulatory signals from genome-wide association studies for type 2 diabetes and glycemic traits to their downstream effectors. PLoS Genet 11:e1005694
87. Gaulton KJ, Ferreira T, Lee Y et al (2015) Genetic fine mapping and genomic annotation defines causal mechanisms at type 2 diabetes susceptibility loci. Nat Genet 47:1415–1425
88. Tuomi T, Nagorny CL, Singh P et al (2016) Increased melatonin signaling is a risk factor for type 2 diabetes. Cell Metab 23:1067–1077
89. Bonnefond A, Clement N, Fawcett K et al (2012) Rare MTNR1B variants impairing melatonin receptor 1B function contribute to type 2 diabetes. Nat Genet 44:297–301
90. Thomsen SK, Ceroni A, van de Bunt M et al (2016) Systematic functional characterization of candidate causal genes for type 2 diabetes risk variants. Diabetes 65:3805–3811